Literature DB >> 15018774

The epidemic of West Nile virus in the United States, 2002.

Daniel R O'Leary1, Anthony A Marfin, Susan P Montgomery, Aaron M Kipp, Jennifer A Lehman, Brad J Biggerstaff, Veronica L Elko, Peggy D Collins, John E Jones, Grant L Campbell.   

Abstract

Since 1999, health officials have documented the spread of West Nile virus across the eastern and southern states and into the central United States. In 2002, a large, multi-state, epidemic of neuroinvasive West Nile illness occurred. Using standardized guidelines, health departments conducted surveillance for West Nile virus illness in humans, and West Nile virus infection and illness in non-human species. Illnesses were reported to the Centers for Disease Control and Prevention (CDC) through the ArboNET system. In 2002, 39 states and the District of Columbia reported 4,156 human West Nile virus illness cases. Of these, 2,942 (71%) were neuroinvasive illnesses (i.e., meningitis, encephalitis, or meningoencephalitis) with onset dates from May 19 through December 14; 1,157 (28%) were uncomplicated West Nile fever cases, and 47 (1%) were clinically unspecified. Over 80% of neuroinvasive illnesses occurred in the central United States. Among meningitis cases, median age was 46 years (range, 3 months to 91 years), and the fatality-to-case ratio was 2%; for encephalitis cases (with or without meningitis), median age was 64 years (range, 1 month to 99 years) and the fatality-to-case ratio was 12%. Neuroinvasive illness incidence and mortality, respectively, were significantly associated with advanced age (p = 0.02; p = 0.01) and being male (p < 0.001; p = 0.002). In 89% of counties reporting neuroinvasive human illnesses, West Nile virus infections were first noted in non-human species, but no human illnesses were reported from 77% of counties in which non-human infections were detected. In 2002, West Nile virus caused the largest recognized epidemic of neuroinvasive arboviral illness in the Western Hemisphere and the largest epidemic of neuroinvasive West Nile virus ever recorded. It is unknown why males appeared to have higher risk of severe illness and death, but possibilities include higher prevalence of co-morbid conditions or behavioral factors leading to increased infection rates. Several observations, including major, multi-state West Nile virus epidemics in 2002 and 2003, suggest that major epidemics may annually reoccur in the United States. Non-human surveillance can warn of early West Nile virus activity and needs continued emphasis, along with control of Culex mosquitoes.

Entities:  

Mesh:

Year:  2004        PMID: 15018774     DOI: 10.1089/153036604773083004

Source DB:  PubMed          Journal:  Vector Borne Zoonotic Dis        ISSN: 1530-3667            Impact factor:   2.133


  72 in total

1.  Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults.

Authors:  Rex Biedenbender; Joan Bevilacqua; Anne M Gregg; Mike Watson; Gustavo Dayan
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

2.  Tissue tropism and neuroinvasion of West Nile virus do not differ for two mouse strains with different survival rates.

Authors:  Ashley N Brown; Kim A Kent; Corey J Bennett; Kristen A Bernard
Journal:  Virology       Date:  2007-08-06       Impact factor: 3.616

3.  Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus.

Authors:  Claire Y-H Huang; Shawn J Silengo; Melissa C Whiteman; Richard M Kinney
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

Review 4.  Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion.

Authors:  Melanie A Samuel; Michael S Diamond
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

5.  A combination of naturally occurring mutations in North American West Nile virus nonstructural protein genes and in the 3' untranslated region alters virus phenotype.

Authors:  C Todd Davis; Sareen E Galbraith; Shuliu Zhang; Melissa C Whiteman; Li Li; Richard M Kinney; Alan D T Barrett
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

6.  Use of a prospective space-time scan statistic to prioritize shigellosis case investigations in an urban jurisdiction.

Authors:  Roderick C Jones; Monica Liberatore; Julio R Fernandez; Susan I Gerber
Journal:  Public Health Rep       Date:  2006 Mar-Apr       Impact factor: 2.792

7.  West Nile virus-associated acute flaccid paralysis.

Authors:  Ashely Alker
Journal:  BMJ Case Rep       Date:  2015-05-02

8.  Safety and pharmacokinetics of single intravenous dose of MGAWN1, a novel monoclonal antibody to West Nile virus.

Authors:  John H Beigel; Jeffrey L Nordstrom; Stanley R Pillemer; Cory Roncal; D Ronald Goldwater; Hua Li; P Chris Holland; Syd Johnson; Kathryn Stein; Scott Koenig
Journal:  Antimicrob Agents Chemother       Date:  2010-03-29       Impact factor: 5.191

9.  Lack of evidence of increased West Nile virus disease severity in the United States in 2012.

Authors:  Nicole P Lindsey; J Erin Staples; Mark J Delorey; Marc Fischer
Journal:  Am J Trop Med Hyg       Date:  2013-11-11       Impact factor: 2.345

10.  A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice.

Authors:  Amelia K Pinto; Justin M Richner; Elizabeth A Poore; Pradnya P Patil; Ian J Amanna; Mark K Slifka; Michael S Diamond
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.